1. Lipid Updates From Spring 2019

2. Burden of Dyslipidemia in ASCVD

3. Lessons From Statin Trials

4. Nonstatin Strategies to Further Reduce LDL-C Ezetimibe

5. Nonstatin Strategies to Further Reduce LDL-C PCSK9 Inhibitors

6. Need for Effective Lipid-Lowering Therapy Beyond a Statin and Challenges Associated With Statin Therapy

7. Statins Foundation of Lipid-Lowering Therapy

8. Lessons Learned From the PCSK9 Inhibitor CV Outcomes Trials

9. PCSK9 Inhibitors are Efficient at Lowering LDL-C

10. PCSK9 Inhibitors Reduce CV Events

11. PCSK9 Inhibitors Are Safe

12. PCSK9 Inhibitors Reported a Clinical Benefit Associated With Very Low LDL-C Levels

13. Re-Evaluating LDL-C Targets

14. Lipid-Lowering Therapy

15. CLEAR Wisdom Trial Bempadoic Acid

16. CLEAR Wisdom Trial Results

17. ORION-4 Design

18. VESALIUS-CV Trial Design

19. Implications for Clinical Care

20. Identifying Which Patient Will Benefit Most From PCSK9 Inhibition

21. 2018 Guidelines on the Management of Blood Cholesterol Secondary Prevention -- PCSK9 Inhibitors

22. Overcoming Access Barriers to PCSK9 Inhibitors

23. Abbreviations

24. Abbreviations (cont)